# Carbamazepine

```text
DRUG INFORMATION

  ADULT
    - Epilepsy ( SEE INDICATIONS AND USAGE ) Adults and children over 12 years of age-
      Initial: Either 200 mg twice a day for tablets and extended-release tablets, or 1
      teaspoon four times a day for suspension (400 mg/day).
      Source: US FDA label for carbamazepine (Carbamazepine), section 'dosage and
      administration', retrieved 2026-08-29
    - Increase at weekly intervals by adding up to 200 mg/day using a twice a day
      regimen of carbamazepine extended-release tablets or a three times a day or four
      times a day regimen of the other formulations until the optimal response is
      obtained.
      Source: US FDA label for carbamazepine (Carbamazepine), section 'dosage and
      administration', retrieved 2026-08-29
    - Doses up to 1600 mg daily have been used in adults in rare instances.
      Source: US FDA label for carbamazepine (Carbamazepine), section 'dosage and
      administration', retrieved 2026-08-29

  CHILD
    - (SEE TABLE BELOW) Carbamazepine suspension in combination with liquid
      chlorpromazine or thioridazine results in precipitate formation, and, in the case
      of chlorpromazine, there has been a report of a patient passing an orange rubbery
      precipitate in the stool following coadministration of the two drugs (see
      PRECAUTIONS, Drug Interactions ).
      Source: US FDA label for carbamazepine (Carbamazepine), section 'dosage and
      administration', retrieved 2026-08-29
    - Epilepsy ( SEE INDICATIONS AND USAGE ) Adults and children over 12 years of age-
      Initial: Either 200 mg twice a day for tablets and extended-release tablets, or 1
      teaspoon four times a day for suspension (400 mg/day).
      Source: US FDA label for carbamazepine (Carbamazepine), section 'dosage and
      administration', retrieved 2026-08-29
    - Dosage generally should not exceed 1000 mg daily in children 12 years to 15 years
      of age, and 1200 mg daily in patients above 15 years of age.
      Source: US FDA label for carbamazepine (Carbamazepine), section 'dosage and
      administration', retrieved 2026-08-29

  RENAL IMPAIRMENT
    - No kidney-impairment dose in this label. Not a statement that none is needed.
      Source: Read and found silent: the US FDA label for carbamazepine (Carbamazepine),
      retrieved 2026-08-29

  HEPATIC IMPAIRMENT
    - No liver-impairment dose in this label. Not a statement that none is needed.
      Source: Read and found silent: the US FDA label for carbamazepine (Carbamazepine),
      retrieved 2026-08-29

  PREGNANCY
    - Nothing on pregnancy in this label. Treat as unknown, not as safe.
      Source: Read and found silent: the US FDA label for carbamazepine (Carbamazepine),
      retrieved 2026-08-29

  BREASTFEEDING
    - Carbamazepine and its epoxide metabolite are transferred to breast milk.
      Source: US FDA label for carbamazepine (Carbamazepine), section 'nursing mothers',
      retrieved 2026-08-29
    - The ratio of the concentration in breast milk to that in maternal plasma is about
      0.4 for carbamazepine and about 0.5 for the epoxide.
      Source: US FDA label for carbamazepine (Carbamazepine), section 'nursing mothers',
      retrieved 2026-08-29
    - The estimated doses given to the newborn during breastfeeding are in the range of
      2 mg to 5 mg daily for carbamazepine and 1 mg to 2 mg daily for the epoxide.
      Source: US FDA label for carbamazepine (Carbamazepine), section 'nursing mothers',
      retrieved 2026-08-29
```

---

Dawaa Reference is a reference for prescribers, not a medical device, and does not replace clinical judgement.

[Privacy policy](/privacy)